Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine In Healthy Adults 65 To 85 Years Of Age

Trial Profile

A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine In Healthy Adults 65 To 85 Years Of Age

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs PF 6425090 (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 02 Aug 2018 Planned End Date changed from 20 Oct 2019 to 25 Oct 2019.
    • 02 Aug 2018 Planned primary completion date changed from 20 Oct 2019 to 25 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top